Getting your player ready...
AstraZeneca Plc, facing expiring patents on its top-selling products, moved closer to winning U.S. approval for a blood thinner to rival Plavix, the world’s second-biggest drug.
Outside advisers to the Food and Drug Administration voted 7-1 Tuesday in favor of using AstraZeneca’s Brilinta to reduce the risk of heart attacks, strokes and death in patients with severe chest pain or earlier heart attacks.
